Endra Life Sciences INC 8-K filings

ENDRA Life Sciences Inc. has received notification from Nasdaq that it has regained compliance with the minimum stockholders equity requirement, avoiding immediate delisting.

ENDRA Life Sciences has entered into a definitive merger agreement with Noble Africa LLC, a subsidiary of ASP Isotopes, to create a combined company focused on helium and LNG resources.

ENDRA Life Sciences announced a merger with Noble Africa LLC, a subsidiary of ASP Isotopes, alongside a $50 million private placement.

Endra Life Sciences Inc. announced a $3.8 million private placement offering of common stock and warrants, aiming to bolster working capital.

ENDRA Life Sciences received a delisting notice from Nasdaq due to insufficient stockholders' equity, despite previous compliance efforts.

ENDRA Life Sciences announced its Q4 and full-year 2025 financial results, reporting reduced operating expenses and net losses, alongside initiating a strategic alternatives review process.

ENDRA Life Sciences Inc. has initiated a review of strategic alternatives to maximize shareholder value, alongside an employee reduction to extend its operational runway.

ENDRA Life Sciences Inc. stockholders approved a significant increase in authorized common stock and an amendment to its incentive plan at the 2025 Annual Meeting.

ENDRA Life Sciences Inc. announced a strategic restructuring of its executive roles, with the Chief Technology Officer transitioning to a consulting role and the Chief Financial Officer's services being formalized through an advisory agreement.

ENDRA Life Sciences Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders' equity requirement following a $4.9 million private placement and other strategic actions.

ENDRA Life Sciences Inc. has entered into an At-The-Market Issuance Sales Agreement to potentially raise up to $1.75 million through common stock sales.

ENDRA Life Sciences Inc. has closed a $4.9 million private placement and launched a digital asset treasury strategy with an initial $3 million investment in HYPE tokens.

ENDRA Life Sciences Inc. announced a $4.9 million private placement to fund a new digital asset treasury strategy and its TAEUS liver device study, while also terminating its ATM sales agreement.

ENDRA Life Sciences Inc. announced a $4.9 million private placement to fund a new digital asset treasury strategy and its TAEUS liver device study.

ENDRA Life Sciences Inc. has authorized a cryptocurrency treasury strategy, engaging institutional partners and forming a dedicated advisory board to manage its digital asset holdings.

ENDRA Life Sciences Inc. has filed a registration statement for a public offering of common stock and warrants, simultaneously disclosing preliminary unaudited financial results for Q2 2025, which include no revenue and an expected operating loss of approximately $1.3 million.

ENDRA Life Sciences Inc. announced on June 11, 2025, that it has posted an investor presentation on its website reflecting a new business strategy previously announced on March 31, 2025.

ENDRA Life Sciences Inc. has been notified by Nasdaq of non-compliance with the minimum stockholders' equity requirement, initiating a process that could lead to delisting.

ENDRA Life Sciences pivots to focus on metabolic disease diagnostics, particularly steatotic liver disease, while reporting reduced cash burn and operating expenses in Q1 2025.

ENDRA Life Sciences reported its Q4 and full-year 2024 financial results, highlighting a strategic pivot towards leveraging its TAEUS technology for early detection and management of metabolic diseases, particularly in patients using GLP-1 therapies.

ENDRA Life Sciences has successfully regained compliance with Nasdaq's minimum bid price requirement, allowing the company to focus on its new business strategies.

ENDRA Life Sciences announced its third quarter 2024 financial results, highlighting a significant reduction in operating expenses and accelerated enrollment in its global multisite pilot study for its TAEUS technology.

ENDRA Life Sciences has completed a 1-for-35 reverse stock split, effective November 7, 2024, to maintain its Nasdaq listing.

ENDRA Life Sciences Inc. has approved a 1-for-35 reverse stock split after receiving shareholder approval at a special meeting.

ENDRA Life Sciences has received an extension from Nasdaq until November 20, 2024, to meet the minimum bid price requirement for continued listing.

ENDRA Life Sciences reported its second quarter 2024 financial results, announced new executive appointments, and detailed a strategic shift towards a more focused clinical and regulatory approach.

ENDRA Life Sciences has enacted a 1-for-50 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

ENDRA Life Sciences announced the resignation of its CEO, the appointment of an acting CEO, and the addition of two new executives to its management team.

ENDRA Life Sciences has appointed a new Head of Finance, increased authorized shares, and approved a 1-for-50 reverse stock split.

ENDRA Life Sciences has received a delisting notice from Nasdaq due to its stock price falling below $0.10, and is seeking a reverse stock split to regain compliance.